Outcomes of LASIK to correct myopia and myopic astigmatism with 500Hz laser system MEL 90

Session Details

Session Title: LASIK I

Session Date/Time: Sunday 06/09/2015 | 08:00-10:00

Paper Time: 08:00

Venue: Room 11

First Author: : J.Gertnere LATVIA

Co Author(s): :    I. Solomatin   A. Solomatin   M. Solomatin              

Abstract Details

Purpose:

To evaluate the clinical outcomes of LASIK to correct myopia or myopic astigmatism using the MEL 90 500Hz eximer laser. In a recent study the results of treatment are investigated in terms of stability, safety, efficacy, and predictability. Additionally investigate the risk of corneal haze appearance.

Setting:

Dr. Solomatin Eye Center, Riga, Latvia

Methods:

This prospective clinical trial comprised 246 eyes from 123 patients. The mean age was 30 years. In this study were included patients with myopia (Sph -0.5 D till -10.0D) and myopic astigmatism ( Cy -0.25 D till -3.0 D) , corrected distance visual acuity (CDVA) of 20/25 or better. All the procedures were performed bilaterally using the eximer laser MEL 90 with Advanced Ablation Algorithm (TripleA). The flap creation was performed using Femtosecond laser VisuMax ot mechanical microceratom Moria II. The follow- up time was 6 months.

Results:

1 months postoperatively, the mean SE was within ±0.5 in 100% and in 98% in 6 months. CDVA ≥20/20 had 96.7% treated eyes in 1month, 95.9 % in 3 months and 95% in 6 months. UDVA ≥ 20/20 had 93.6% of eyes in 1 month , 93.9% in 3 months and 91% in 6 months. Safety, in 1 month 91.9 % unchanged or gained lines, 95,2% in 3 months and 92,4% in 6 months. 0% of eyes lost 2 lines. No any haze case, no any complications or adverse events.

Conclusions:

The LASIK with Triple A ablation profile performed with 500 Hz eximer laser for correcting of low, moderate and high myopia with or without astigmatism shows good results in terms of efficacy, stability, predictability and safety. No specific side effects that might be associated with a high repetition rate occurred.

Financial Interest:

One of the authors research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented